{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:16:13Z","timestamp":1769840173810,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"am","delay-in-days":358,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.vaccine.2022.06.079","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T08:04:05Z","timestamp":1658736245000},"page":"5160-5169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-\/- mice"],"prefix":"10.1016","volume":"40","author":[{"given":"Martha M.","family":"O'Kennedy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Coetzee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otto","family":"Koekemoer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lissinda","family":"du Plessis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carina W.","family":"Lourens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lusisizwe","family":"Kwezi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilse","family":"du Preez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sipho","family":"Mamputha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobalanda B.","family":"Mokoena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daria A.","family":"Rutkowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan A.","family":"Verschoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolandy","family":"Lemmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.06.079_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/viro.1996.0028","article-title":"Orbivirus structure and assembly","volume":"216","author":"Roy","year":"1996","journal-title":"Minirev Virol"},{"key":"10.1016\/j.vaccine.2022.06.079_b0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.trivac.2015.03.001","article-title":"Immunization of horses with a polyvalent live-attenuated African horse sickness vaccine: serological response and disease occurrence under field conditions","volume":"4","author":"Molini","year":"2015","journal-title":"Trials Vaccinol"},{"issue":"10","key":"10.1016\/j.vaccine.2022.06.079_b0015","article-title":"Assessing the potential of plains zebra to maintain African horse sickness in the Western Cape Province","volume":"14","author":"Porphyre","year":"2019","journal-title":"South Africa PlosOne"},{"key":"10.1016\/j.vaccine.2022.06.079_b0020","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s12917-020-02540-y","article-title":"Immune response of horses to inactivated African horse sickness vaccines","volume":"16","author":"Rodr\u00edguez","year":"2020","journal-title":"BMC Veterinary Res"},{"key":"10.1016\/j.vaccine.2022.06.079_b0025","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1016\/j.vaccine.2017.04.005","article-title":"Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralizing antibodies (VNAb) in horses when administered in combination","volume":"35","author":"Manning","year":"2017","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2022.06.079_b0030","doi-asserted-by":"crossref","DOI":"10.3201\/eid2212.160718","article-title":"African horse sickness caused by genome reassortment and reversion to virulence of live, attenuated vaccine viruses, South Africa, 2004\u20132014","volume":"22","author":"Weyer","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2022.06.079_b0035","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1016\/j.vaccine.2014.04.087","article-title":"Serological response of foals to polyvalent and monovalent live-attenuated African horse sickness virus vaccines","volume":"32","author":"Crafford","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.079_b0040","doi-asserted-by":"crossref","first-page":"7108","DOI":"10.1016\/j.vaccine.2020.08.072","article-title":"Safety and efficacy of inactivated African horse sickness (AHS) vaccine formulated with different adjuvants","volume":"38","author":"Van Rijn","year":"2020","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.079_b0045","first-page":"89","article-title":"Inactivated and adjuvanted vaccine for the control of the African horse sickness virus serotype 9 infection: Evaluation of efficacy in horses and guinea-pig model","volume":"49","author":"Lelli","year":"2013","journal-title":"Veterinaria Italiana"},{"issue":"6","key":"10.1016\/j.vaccine.2022.06.079_b0050","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.1371\/journal.pone.0005997","article-title":"Induction of antibody responses to African Horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA)","volume":"4","author":"Chiam","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2022.06.079_b0055","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1016\/j.vaccine.2009.05.044","article-title":"Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing gene encoding the outer capsid proteins of African horse sickness virus","volume":"27","author":"Guthrie","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.079_b0060","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.virusres.2013.12.002","article-title":"Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation","volume":"180","author":"Calvo-Pinilla","year":"2014","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2022.06.079_b0065","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2018.04.015","article-title":"The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host","volume":"154","author":"Calvo-Pinilla","year":"2018","journal-title":"Antiviral Res"},{"issue":"1","key":"10.1016\/j.vaccine.2022.06.079_b0070","doi-asserted-by":"crossref","first-page":"16503","DOI":"10.1371\/journal.pone.0016503","article-title":"A modified Vaccinia Ankara Virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR-\/- mouse model","volume":"6","author":"Castillo-Olivares","year":"2011","journal-title":"PlosOne"},{"key":"10.1016\/j.vaccine.2022.06.079_b0075","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1016\/j.vaccine.2014.04.036","article-title":"Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge","volume":"32","author":"Alberca","year":"2014","journal-title":"Vaccine"},{"issue":"33","key":"10.1016\/j.vaccine.2022.06.079_b0080","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1016\/j.vaccine.2017.06.023","article-title":"Protective efficacy of multivalent replication-abortive vaccine strains in horses against African horse sickness virus challenge","volume":"35","author":"Lulla","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.079_b0085","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1016\/j.vaccine.2021.04.034","article-title":"Entry-competent-replication-abortive African horse sickness virus strains elicit robust immunity in ponies against all serotypes","volume":"39","author":"Sullivan","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.079_b0090","doi-asserted-by":"crossref","first-page":"8764","DOI":"10.1128\/JVI.01052-15","article-title":"VP2 exchange and NS3\/NS3a deletion in African Horse Sickness Virus (AHSV) in development of disabled infectious single animal vaccine candidates for AHSV","volume":"89","author":"van de Water SGP, van Gennip RGP, Potgieter CA, Wright IM and van Rijn PA","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.06.079_b0095","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.vaccine.2018.03.003","article-title":"African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3\/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform","author":"Van Rijn","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.079_b0100","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.virusres.2015.12.006","article-title":"Synthesis of empty African horse sickness virus particles","volume":"213","author":"Maree","year":"2016","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2022.06.079_b0105","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1099\/0022-1317-77-6-1211","article-title":"Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7","volume":"77","author":"Mart\u00ednez-Torrecuadrada","year":"1996","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2022.06.079_b0110","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1099\/0022-1317-77-9-2053","article-title":"Recombinant baculovirus-synthesised African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against lethal AHSV challenge","volume":"77","author":"Roy","year":"1996","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2022.06.079_b0115","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0264-410X(01)00445-5","article-title":"The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant","volume":"20","author":"Scanlen","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.079_b0120","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.1016\/j.vaccine.2014.07.031","article-title":"Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus","volume":"32","author":"Kanai","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.079_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2018.09.065","article-title":"A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model","author":"Aksular","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.079_b0130","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/pbi.12783","article-title":"Immunogenicity of plant-produced African horse sickness virus-like particles: implications for a novel vaccine","volume":"16","author":"Dennis","year":"2017","journal-title":"Plant Biotech J"},{"key":"10.1016\/j.vaccine.2022.06.079_b0135","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13567-018-0600-4","article-title":"Safety and immunogenicity of plant-produced African horse sickness virus-like particles in horses","volume":"49","author":"Dennis","year":"2018","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2022.06.079_b0140","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/s12917-019-2184-2","article-title":"Plant produced chimaeric VLPs - a new generation vaccine against African Horse Sickness","volume":"15","author":"Rutkowska","year":"2019","journal-title":"BMC Veterinary Res"},{"key":"10.1016\/j.vaccine.2022.06.079_b0145","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J Nanobiotechnol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.06.079_b0150","article-title":"Bluetongue virus outer-capsid protein VP2 expressed in Nicotiana benthamiana raises neutralising antibodies and a protective immune response in IFNAR -\/- mice","volume":"22","author":"Fay","year":"2019","journal-title":"Vaccine X"},{"key":"10.1016\/j.vaccine.2022.06.079_b0155","first-page":"235","article-title":"Structural studies of orbivirus particles","volume":"14","author":"Stuart","year":"1998","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2022.06.079_b0160","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1467-7652.2008.00330.x","article-title":"Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure","volume":"6","author":"Strasser","year":"2008","journal-title":"Plant Biotechnol J"},{"key":"10.1016\/j.vaccine.2022.06.079_b0165","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.virusres.2015.08.005","article-title":"Identification of CD8 T cells epitopes in VP2 and NS1 proteins of African horse sickness virus in IFNAR (-\/-) mice","volume":"210","author":"De la Poza","year":"2015","journal-title":"Virus Res"},{"issue":"7","key":"10.1016\/j.vaccine.2022.06.079_b0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070197","article-title":"NS1 is a key protein in the vaccine composition to protect IFNAR-\/- mice against infection with multiple-serotypes of African horse sickness virus","volume":"8","author":"De la Poza","year":"2013","journal-title":"PLoS ONE"},{"issue":"35","key":"10.1016\/j.vaccine.2022.06.079_b0175","first-page":"1","article-title":"Modeling arboviral infection in mice lacking the interferon alpha\/beta receptor","volume":"11","author":"Mar\u00edn-Lopez","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2022.06.079_b0180","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.vetmic.2014.10.006","article-title":"Study of the virulence of serotypes 4 and 9 of African horse sickness virus in IRNAR-\/-, Balb\/C and 129 Sv\/Ev mice","volume":"174","author":"De la Grandi\u00e8re","year":"2014","journal-title":"Vet Microbiol"},{"issue":"41","key":"10.1016\/j.vaccine.2022.06.079_b0185","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1016\/j.vaccine.2019.08.042","article-title":"Plant produced Bluetongue VLP vaccine candidates elicits serotype specific immunity in sheep","volume":"37","author":"Mokoena","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.06.079_b0190","doi-asserted-by":"crossref","unstructured":"Bahneman, H.G., 1990. Inactivation of viral antigens for vaccine preparation with reference to application of binary ethylenimine. Vaccine 1990;8:299\u2013303.","DOI":"10.1016\/0264-410X(90)90083-X"},{"key":"10.1016\/j.vaccine.2022.06.079_b0195","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jviromet.2015.07.015","article-title":"Development of three triplex real-time reverse transcription PCR assays for the qualitative molecular typing of nine serotypes of African horse sickness virus","volume":"223","author":"Weyer","year":"2015","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2022.06.079_b0200","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.1016\/j.vaccine.2010.06.105","article-title":"In vivo cross-protection to African Horse Sickness serotypes 5 and 9 after vaccination with serotypes 8 and 6","volume":"28","author":"Von Teichman","year":"2010","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22008489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22008489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:14:54Z","timestamp":1759403694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22008489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":40,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0264410X22008489"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.079","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-\/- mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}